eliglustat-tartrate and Angiokeratoma

Angiokeratomas are the cutaneous hallmark of Fabry disease. Although it is well established that enzyme replacement therapy (ERT) prevents or slows the progression of disease on target organs in the majority of patients, the long-term effect of ERT on angiokeratomas remains unknown. We present a patient diagnosed with Fabry disease at age 11, with rapid progression of new angiokeratomas in typical regions before beginning treatment with ERT. To date, our patient has been treated with ERT for 10 years. During the treatment period, new angiokeratomas have not arisen nor have existing ones enlarged during puberty, adolescence, and early adulthood. Furthermore, partial regression of the angiokeratomas has occurred in association with regression of left ventricular hypertrophy and anhidrosis. Overall, this case suggests that long-term ERT could stop the progression of angiokeratomas and induce their partial regression but does not produce complete resolution. Importantly, regression of angiokeratomas might be a marker of systemic target-organ efficacy of ERT.

Topics: alpha-Galactosidase; Angiokeratoma; Enzyme Replacement Therapy; Fabry Disease; Humans; Isoenzymes; Male; Recombinant Proteins; Skin Neoplasms; Young Adult

Topics: Adult; alpha-Galactosidase; Angiokeratoma; Enzyme Replacement Therapy; Fabry Disease; Humans; Isoenzymes; Male; Remission Induction; Scrotum; Skin Neoplasms; Treatment Outcome

Topics: Adolescent; Adult; alpha-Galactosidase; Angiokeratoma; Child; Child, Preschool; Diagnosis, Differential; Fabry Disease; Family Practice; Humans; Infant; Infant, Newborn; Isoenzymes; Male